FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2612316483> ?p ?o ?g. }

• W2612316483 endingPage "842" @default.
• W2612316483 startingPage "834" @default.
• W2612316483 abstract "Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit.We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients. CGP was performed on formalin-fixed, paraffin-embedded sections from 41 consecutive clinical cases of ENBs using a hybrid-capture, adaptor ligation based next-generation sequencing assay to a mean coverage depth of 593X. The results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes (amplifications and homozygous deletions).Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in clinical trials. A total of 28 ENBs harbored GA, with a mean of 1.5 GA per sample. Approximately half of the ENBs (21, 51%) featured at least one CRGA, with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17%), with GA in PIK3CA, NF1, CDKN2A, and CDKN2C occurring in 7% of samples.We report comprehensive genomic profiles for 41 ENB tumors. CGP revealed potential new therapeutic targets, including targetable GA in the mTOR, CDK and growth factor signaling pathways, highlighting the clinical value of genomic profiling in ENB.Comprehensive genomic profiling of 41 relapsed or refractory ENBs reveals recurrent alterations or classes of mutation, including amplification of tyrosine kinases encoded on chromosome 5q and mutations affecting genes in the mTOR/PI3K pathway. Approximately half of the ENBs (21, 51%) featured at least one clinically relevant genomic alteration (CRGA), with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17%), and alterations in PIK3CA, NF1, CDKN2A, or CDKN2C were identified in 7% of samples. Responses to treatment with the kinase inhibitors sunitinib, everolimus, and pazopanib are presented in conjunction with tumor genomics." @default.
• W2612316483 created "2017-05-19" @default.
• W2612316483 creator A5003240554 @default.
• W2612316483 creator A5011609796 @default.
• W2612316483 creator A5018411858 @default.
• W2612316483 creator A5021626755 @default.
• W2612316483 creator A5035120516 @default.
• W2612316483 creator A5038295657 @default.
• W2612316483 creator A5043772371 @default.
• W2612316483 creator A5053987349 @default.
• W2612316483 creator A5056157669 @default.
• W2612316483 creator A5056817906 @default.
• W2612316483 creator A5057155689 @default.
• W2612316483 creator A5062006821 @default.
• W2612316483 creator A5073432388 @default.
• W2612316483 creator A5088559019 @default.
• W2612316483 creator A5088809839 @default.
• W2612316483 creator A5091071176 @default.
• W2612316483 date "2017-05-11" @default.
• W2612316483 modified "2023-09-24" @default.
• W2612316483 title "Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options" @default.
• W2612316483 cites W1638528055 @default.
• W2612316483 cites W1965449253 @default.
• W2612316483 cites W1969398614 @default.
• W2612316483 cites W1970827198 @default.
• W2612316483 cites W1989773675 @default.
• W2612316483 cites W2015716017 @default.
• W2612316483 cites W2019044121 @default.
• W2612316483 cites W2030438695 @default.
• W2612316483 cites W2049226186 @default.
• W2612316483 cites W2053229096 @default.
• W2612316483 cites W2064430445 @default.
• W2612316483 cites W2072311353 @default.
• W2612316483 cites W2142205677 @default.
• W2612316483 cites W2160981405 @default.
• W2612316483 cites W2169512997 @default.
• W2612316483 cites W2294723338 @default.
• W2612316483 cites W2320384263 @default.
• W2612316483 cites W2395841761 @default.
• W2612316483 cites W2411894166 @default.
• W2612316483 cites W2416977088 @default.
• W2612316483 cites W2418054261 @default.
• W2612316483 doi "https://doi.org/10.1634/theoncologist.2016-0287" @default.
• W2612316483 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5507647" @default.
• W2612316483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28495808" @default.
• W2612316483 hasPublicationYear "2017" @default.
• W2612316483 type Work @default.
• W2612316483 sameAs 2612316483 @default.
• W2612316483 citedByCount "29" @default.
• W2612316483 countsByYear W26123164832018 @default.
• W2612316483 countsByYear W26123164832019 @default.
• W2612316483 countsByYear W26123164832020 @default.
• W2612316483 countsByYear W26123164832021 @default.
• W2612316483 countsByYear W26123164832022 @default.
• W2612316483 countsByYear W26123164832023 @default.
• W2612316483 crossrefType "journal-article" @default.
• W2612316483 hasAuthorship W2612316483A5003240554 @default.
• W2612316483 hasAuthorship W2612316483A5011609796 @default.
• W2612316483 hasAuthorship W2612316483A5018411858 @default.
• W2612316483 hasAuthorship W2612316483A5021626755 @default.
• W2612316483 hasAuthorship W2612316483A5035120516 @default.
• W2612316483 hasAuthorship W2612316483A5038295657 @default.
• W2612316483 hasAuthorship W2612316483A5043772371 @default.
• W2612316483 hasAuthorship W2612316483A5053987349 @default.
• W2612316483 hasAuthorship W2612316483A5056157669 @default.
• W2612316483 hasAuthorship W2612316483A5056817906 @default.
• W2612316483 hasAuthorship W2612316483A5057155689 @default.
• W2612316483 hasAuthorship W2612316483A5062006821 @default.
• W2612316483 hasAuthorship W2612316483A5073432388 @default.
• W2612316483 hasAuthorship W2612316483A5088559019 @default.
• W2612316483 hasAuthorship W2612316483A5088809839 @default.
• W2612316483 hasAuthorship W2612316483A5091071176 @default.
• W2612316483 hasBestOaLocation W26123164831 @default.
• W2612316483 hasConcept C104317684 @default.
• W2612316483 hasConcept C120821319 @default.
• W2612316483 hasConcept C126322002 @default.
• W2612316483 hasConcept C141231307 @default.
• W2612316483 hasConcept C150194340 @default.
• W2612316483 hasConcept C18431079 @default.
• W2612316483 hasConcept C2777609662 @default.
• W2612316483 hasConcept C2780265364 @default.
• W2612316483 hasConcept C2781088518 @default.
• W2612316483 hasConcept C502942594 @default.
• W2612316483 hasConcept C509974204 @default.
• W2612316483 hasConcept C54355233 @default.
• W2612316483 hasConcept C62478195 @default.
• W2612316483 hasConcept C71924100 @default.
• W2612316483 hasConcept C86554907 @default.
• W2612316483 hasConcept C86803240 @default.
• W2612316483 hasConceptScore W2612316483C104317684 @default.
• W2612316483 hasConceptScore W2612316483C120821319 @default.
• W2612316483 hasConceptScore W2612316483C126322002 @default.
• W2612316483 hasConceptScore W2612316483C141231307 @default.
• W2612316483 hasConceptScore W2612316483C150194340 @default.
• W2612316483 hasConceptScore W2612316483C18431079 @default.
• W2612316483 hasConceptScore W2612316483C2777609662 @default.
• W2612316483 hasConceptScore W2612316483C2780265364 @default.
• W2612316483 hasConceptScore W2612316483C2781088518 @default.

• next